Cross-priming serves to activate cytotoxic T lymphocytes for immune defense against viruses and tumors and plays an important role in vaccinations. Only certain DC subsets can cross-present and these are characterized by expression of cell surface markers like CD8a, CD24 CD103, BDCA-3 or XCR1. Classifying DC ...
Cross-priming serves to activate cytotoxic T lymphocytes for immune defense against viruses and tumors and plays an important role in vaccinations. Only certain DC subsets can cross-present and these are characterized by expression of cell surface markers like CD8a, CD24 CD103, BDCA-3 or XCR1. Classifying DC subsets by such markers is convenient for flow-cytometric analysis, but does not mechanistically explain why a cell can cross-present. Recent studies have proposed two mechanistic explanations, which are not mutually exclusive: 1. only cross-presenting DCs possess the antigen processing machinery that loads endocytosed antigen onto MHC class I molecules (e.g. by proteases like IRAP). 2. cross-presentation depends on distinct endocytosis mechanisms (Mannose receptor, DNGR1, DC-SIGN, DEC205) (CD205) that can introduce antigen directly into distinct organelle(s) in which cross-presentation occurs. This Research Topic is focused on articles that can help understanding how cross-presentation occurs mechanistically, with a special emphasis on further endocytosis receptors, intracellular organelles and molecular antigen processing or membrane translocation mechanisms that can facilitate or are associated with cross-presentation and that can be exploited for vaccine optimization.
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.